TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02638272

Intervention type: PROCEDURE
Group type: OTHER
Intervention: no debridement
Description: It is a spinal surgery performed with isolated posterior instrumentation without debridement.
Study: NCT02843750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training-Rehabilitation
Description: The training will include the following components:~1. Breathing Awareness~2. Upper and Lower Extremity Exercise.~3. Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~4. Practice at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
Study: NCT02235909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Low-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Low-dose

Intervention type: DRUG
Group type: OTHER
Intervention: Azilsartan Medoxomil Low-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Low-dose
Study: NCT04815733

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandatory ventilation
Description: Use PCV-VG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure support ventilation
Description: Use PSVpro
Study: NCT03948269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group behavioral cognitive therapy
Description: First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group behavioral cognitive therapy
Description: First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
Study: NCT03029039

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at inclusion.

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at inclusion.
Study: NCT00178698

Intervention type: OTHER
Group type: OTHER
Intervention: thermochemotherapy
Description: cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin, Gemcitabine, Interferon-a
Description: cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration

Intervention type: OTHER
Group type: OTHER
Intervention: thermochemotherapy
Description: After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
Study: NCT03184662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIPA
Description: inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months
Study: NCT04424316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01465451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: curative resection for colorectal cancer
Description: right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
Study: NCT03184662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling PA
Description: Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
Study: NCT01245686

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and medication intervention
Description: The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and medication intervention
Description: The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
Study: NCT02886507

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NSK-SD (nattokinase)
Description: Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules contain microcrystalline cellulose.
Study: NCT03001193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF 01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF 01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF 01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03572231

Intervention type: DRUG
Intervention: mirabegron
Description: oral

Intervention type: DEVICE
Intervention: solifenacin
Description: oral

Intervention type: DRUG
Intervention: darifenacin
Description: oral

Intervention type: DRUG
Intervention: imidafenacin
Description: oral

Intervention type: DRUG
Intervention: tolterodine
Description: oral

Intervention type: DRUG
Intervention: oxybutynin
Description: oral
Study: NCT02235909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan Medoxomil Low-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study: NCT01465451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curative resection for colorectal cancer
Description: right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-operative 5-FU chemotherapy
Description: 5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A.
Study: NCT01543113

Intervention type: OTHER
Group type: OTHER
Intervention: sequencing
Description: sequencing
Study: NCT02763241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cleanoze®
Description: Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline (Syringe irrigation)
Description: Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
Study: NCT02357888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0018
Description: Oromucosal - Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0018
Description: Oromucosal - Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oromucosal - Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oromucosal - Single dose
Study: NCT04466813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention-Dry Needling
Description: Deep Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle.~1 session in upper trapezius muscle moving the needle up and down ten times.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control-Dry Needling
Description: Sham Dry Needling into the site of the latent Trigger Point of the upper trapezius muscle with non-penetrating needles
Study: NCT01020968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
Study: NCT00587834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gintuit
Description: Application of Gintuit at Day 0 to the gingival bed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous palatal tissue
Description: Tissue will be harvested from the subject's palate and placed on the gingival bed
Study: NCT00636441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
Description: Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
Description: Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
Study: NCT03915106

Intervention type: DEVICE
Intervention: Brace
Description: Wear a rigid brace

Intervention type: PROCEDURE
Intervention: Surgical correction using implants
Description: Surgical correction of spine using implants (metallic rods and metallic screws)
Study: NCT02235909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Azilsartan Medoxomil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Azilsartan Medoxomil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Losartan

Intervention type: DRUG
Group type: OTHER
Intervention: antihypertension medication - Add-on Therapy
Description: add-on therapy (e.g., a calcium channel blocker, such as amlodipine, a diuretic, such as hydrochlorothiazide, or a beta-blocker such as metoprolol) per PI's clinical judgment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Medium-dose
Study: NCT00334204

Intervention type: DEVICE
Group type: OTHER
Intervention: measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
Description: measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
Study: NCT04615780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouthwash with green tea
Description: All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The intervention group rinsed the mouth with 100 ml green tea solution for 60 seconds at least twice daily. For the preparation of the green tea mouthwash, green tea solution was made with 5 g (1 teaspoon) of green tea powder dissolved in 100 ml water to produce 5% green tea mouthwash, as described in a previous study (Eshghpour, et al., 2013). The green tea powder was ground from Camelia sinensis leaves and regularly provided by the researcher. The green tea solution is made for a single use and remade before rinsing each time. When patients return to the outpatient monthly, the researcher first confirms patients' compliance, then assists with solving difficulties and gives encouragement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mouthwash with tap water group
Description: All patients received instructions for using the Bass brushing method to brush their teeth with a soft small-headed toothbrush. The control group rinsed the mouth with 100 ml tap water for 60 seconds at least twice daily.
Study: NCT03288441

Intervention type: DRUG
Intervention: Hold
Description: Hold antithrombotic therapy
Study: NCT02235909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Medium-dose
Study: NCT03288441

Intervention type: DRUG
Intervention: Hold
Description: Hold antithrombotic therapy

Intervention type: DRUG
Intervention: Prophylactic dose antithrombotic
Description: Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
Study: NCT02235909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil High-dose
Study: NCT03572231

Intervention type: DRUG
Intervention: trospium
Description: oral

Intervention type: DRUG
Intervention: fesoterodine
Description: oral

Intervention type: DEVICE
Intervention: propiverine
Description: oral
Study: NCT01894724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroSave device
Study: NCT03288441

Intervention type: DRUG
Intervention: Change antithrombotic Drug
Description: Change in type of antithrombotic therapy

Intervention type: DRUG
Intervention: Change antithrombotic Drug
Description: Change in type of antithrombotic therapy
Study: NCT00707720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TERIS procedure
Description: The implantation of the restrictive implant
Study: NCT03148379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized patient instruments
Description: Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Metal Instruments
Description: Traditional metal instrument will be used to make bone cuts and size the components in this control group.
Study: NCT03288441

Intervention type: BIOLOGICAL
Intervention: Change platelet transfusion threshold
Description: Increase or reduce platelet transfusion threshold
Study: NCT00318630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
Study: NCT01539122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer TM Glenoid
Description: The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Glenoid
Description: A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
Study: NCT02020434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPX7009 and RPX2014
Description: The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
Study: NCT04491435

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Summated Xerostomia Inventory
Description: structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Summated Xerostomia Inventory
Description: structured interview by a dedicated researcher to obtain a score of the summated xerostomia inventory (SXI)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Sialometry
Description: unstimulated whole saliva (UWS) flow measurement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sialometry
Description: unstimulated whole saliva (UWS) flow measurement
Study: NCT03316716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active warming
Description: Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
Study: NCT01131806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/ salmeterol 125/25 mcg/puff
Description: fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/ salmeterol 250/25 mcg/puff
Description: fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
Study: NCT04643587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL787
Description: Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL787
Description: Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL787
Description: Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL787
Description: Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL787
Description: Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL787
Description: Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL787
Description: Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% NaCl)
Study: NCT00318630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo oral tablet.